N
CMPX icon

Nuveen’s Compass Therapeutics CMPX Stock Holding History

Nuveen’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.54M Buy
290,972
+2,048
+0.7% +$11.8K ﹤0.01% 2376
2025
Q4 		$1.55M Buy
288,924
+29,713
+11% +$137K ﹤0.01% 2403
2025
Q3 		$907K Hold
259,211
– – ﹤0.01% 2668
2025
Q2 		$674K Sell
259,211
-45,293
-15% -$93.4K ﹤0.01% 2778
2025
Q1 		$579K Hold
304,504
– – ﹤0.01% 2855
2024
Q4 		$442K Hold
304,504
– – ﹤0.01% 3025
2024
Q3 		$560K Hold
304,504
– – ﹤0.01% 2977
2024
Q2 		$305K Hold
304,504
– – ﹤0.01% 3148
2024
Q1 		$603K Hold
304,504
– – ﹤0.01% 2913
2023
Q4 		$475K Sell
304,504
-93,030
-23% -$161K ﹤0.01% 3019
2023
Q3 		$783K Buy
397,534
+5,663
+1% +$14K ﹤0.01% 2671
2023
Q2 		$1.25M Buy
+391,871
New +$1.23M ﹤0.01% 2561

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nuveen's CMPX Position: Q1 2026 in Review

Nuveen increased its Compass Therapeutics (CMPX) stake by 0.71% in Q1 2026, buying an estimated $11.8K and bringing the position to 290,972 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2376.

Nuveen first reported a position in CMPX in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.55M in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Nuveen held 290,972 shares of Compass Therapeutics worth $1.54M as of Q1 2026.
  • Nuveen bought 2,048 Compass Therapeutics shares in Q1 2026, an estimated $11.8K.
  • Compass Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2376 holding.
  • Nuveen first reported a position in Compass Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Nuveen's Compass Therapeutics position peaked at $1.55M in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.